Literature DB >> 9620601

The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells.

J A Kaleeba1, H Offner, A A Vandenbark, A Lublinski, A D Weinberg.   

Abstract

The OX-40 receptor, a member of the nerve growth factor/tumor necrosis factor receptor gene family, is expressed preferentially on autoreactive CD4+ T cells isolated from the site of inflammation in rats with clinical signs of experimental autoimmune encephalomyelitis (EAE). To examine whether the OX-40 receptor has biologic relevance to T cell function, we evaluated the ability of a rat OX-40 receptor-specific antibody to co-stimulate a myelin basic protein (MBP)-reactive CD4+ T cell line. The anti-OX-40 antibody provided a potent co-stimulatory signal to CD4+ T cells when added in conjunction with a submitogenic dose of anti-CD3, but the anti-OX-40 antibody alone did not produce a mitogenic response. The magnitude and dose-response of anti-OX-40 co-stimulation was virtually identical to the signal delivered to T cells when cultured with anti-CD28 in conjunction with anti-CD3. MBP-specific T cells stimulated with both anti-CD3 and anti-OX-40 antibodies expressed increased mRNA and protein for IL-2 when compared to anti-CD3 alone. MBP-specific T cells stimulated with both anti-CD3 and anti-OX-40 antibodies were also able to induce EAE when transferred into naive Lewis rats. In contrast, cells stimulated with anti-CD3 alone were not encephalitogenic. These data suggest that the function of the OX-40 receptor on activated T cells is to provide an alternative pathway for T cell co-stimulation that may be similar in potency to the CD28-mediated signal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620601     DOI: 10.1093/intimm/10.4.453

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  13 in total

1.  CD28-independent induction of experimental autoimmune encephalomyelitis.

Authors:  T Chitnis; N Najafian; K A Abdallah; V Dong; H Yagita; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.

Authors:  Francisco J Quintana; Doron Gerber; Sally C Kent; Irun R Cohen; Yechiel Shai
Journal:  J Clin Invest       Date:  2005-07-07       Impact factor: 14.808

3.  CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Authors:  Harry Z Qui; Adam T Hagymasi; Suman Bandyopadhyay; Marie-Clare St Rose; Raghunath Ramanarasimhaiah; Antoine Ménoret; Robert S Mittler; Scott M Gordon; Steven L Reiner; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2011-08-31       Impact factor: 5.422

4.  Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.

Authors:  Nicholas P Morris; Carmen Peters; Ryan Montler; Hong-Ming Hu; Brendan D Curti; Walter J Urba; Andrew D Weinberg
Journal:  Mol Immunol       Date:  2007-03-19       Impact factor: 4.407

5.  A novel adjuvant for vaccine development in the aged.

Authors:  Edward L Morgan; Marilyn L Thoman; Sam D Sanderson; Joy A Phillips
Journal:  Vaccine       Date:  2010-10-19       Impact factor: 3.641

6.  The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.

Authors:  D S Vinay; B S Kwon
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

Review 7.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

8.  HIV-1 gp41 and TCRalpha trans-membrane domains share a motif exploited by the HIV virus to modulate T-cell proliferation.

Authors:  Tomer Cohen; Shmuel Jaffe Cohen; Niv Antonovsky; Irun R Cohen; Yechiel Shai
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

9.  OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade.

Authors:  Bryna E Burrell; Guanyi Lu; Xian C Li; D Keith Bishop
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

Review 10.  [Immunmodulatory antibodies in the treatment of skin cancer].

Authors:  D Schrama; A Hauschild; J C Becker
Journal:  Hautarzt       Date:  2008-10       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.